Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

On April 11, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA®, Merck Inc.) for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLC. Patients’ tumors must have no EGFR or ALK genomic aberrations and express PD-L1 (Tumor Proportion Score [TPS] ≥1%) determined by an FDA-approved test.
For many oncology patients, the home setting is typically a place for recovery following treatment for cancer. At times, this recovery is supported with formal home care services such as nurse and physical therapy visits, infusion services, and so forth. In the latest blog post, The Hospital at Home: A Bright Prospect for Oncology Care? Heather Hylton, MS, PA-C, examines this innovative paradigm that could enable patients to receive acute care in the home setting.
ASCO’s online community platform, myConnection, provides ASCO members with the opportunity to connect, collaborate, participate in in-depth discussions, and receive feedback and resources with the nearly 45,000 members in ASCO’s global network. We know the value ASCO members put on networking and collaboration, and we are excited to provide ASCO members with an environment to connect and engage in real time.
ASCO’s new “Rural Cancer Care Task Force” will identify opportunities to reduce disparities and improve outcomes for patients and survivors of cancer who live in rural communities.
This is the first year that Quality Payment Program performance information will be publicly reported, so the Centers for Medicare & Medicaid Services is offering a supplemental Physician Compare preview period. Eligible clinicians and groups are encouraged to check their performance information before the preview period closes on April 27. Learn more. 
The Centers for Disease Control and Prevention (CDC) issued a key clarification on its Guideline for Prescribing Opioids for Chronic Pain. The clarification comes as a result of a collaborative effort by ASCO, the American Society of Hematology (ASH), CDC, and the National Comprehensive Cancer Network (NCCN) to clarify CDC’s opioid prescribing guideline to ensure appropriate implementation for people with cancer, cancer survivors, and patients with sickle cell disease.
As part of its approach to reduce the burden of cancer faced by patients worldwide, ASCO is seeking host practices outside the U.S. for its one-day Quality Training Program (QTP) workshop. The QTP is designed to prepare oncology care teams to design, implement, and lead successful quality improvement activities in their practice settings. To date, more than 100 teams from around the world have participated in the program.
U.S. physicians have from April 1 until May 15 to review and dispute Open Payments data before it is made public on June 30. Review of the data is voluntary, but strongly encouraged to help improve the accuracy of the reported data. Learn more about Open Payments Review and Dispute here.